{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/polymyalgia-rheumatica/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"45868673-afab-57d2-a5d7-8e82c7a6a1d6","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field f0e9f6a6-29de-48d4-9860-07561f3b90c2 --><h2>Changes</h2><!-- end field f0e9f6a6-29de-48d4-9860-07561f3b90c2 -->","summary":null,"htmlStringContent":"<!-- begin item 73736b02-bd72-4a66-994a-71563675d788 --><!-- begin field a923b85b-332c-413e-96e9-a90451d0a4ef --><p><strong>January 2019 </strong>— reviewed. A literature search was conducted in January 2019 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. No major changes to clinical recommendations have been made.</p><!-- end field a923b85b-332c-413e-96e9-a90451d0a4ef --><!-- end item 73736b02-bd72-4a66-994a-71563675d788 -->","topic":{"id":"ce8b01ca-f53a-55a3-8d34-3f1c4627fe6a","topicId":"ad21d80a-1ea5-4ead-b50d-c84a90f81dfd","topicName":"Polymyalgia rheumatica","slug":"polymyalgia-rheumatica","lastRevised":"Last revised in January 2019","chapters":[{"id":"1422f739-c18d-5e1e-a304-97c38c53326d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"16d2834f-dff7-5cdb-a7f4-58e78255d2d2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e0b8f18b-6f9c-5652-83d0-dafbd8f023f1","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"45868673-afab-57d2-a5d7-8e82c7a6a1d6","slug":"changes","fullItemName":"Changes"},{"id":"5b1ee373-bd86-5e9d-812b-4832f6246571","slug":"update","fullItemName":"Update"}]},{"id":"27cf37e3-9a75-54bf-b40c-a9a5d3ab8774","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f98bc06e-32e0-5d1b-955b-704d835dadfc","slug":"goals","fullItemName":"Goals"},{"id":"de16a1ee-5b79-561d-aa33-007310d41806","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"27fd23e5-8ea0-5fc4-a238-92290ecf2d96","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"07ae7b26-b61c-5b1d-a11a-2e2f8831b2b4","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"40fc7a60-984c-568d-bca4-9c74b0dd12ad","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"51474ce0-d36a-55b4-be78-dce9cacb0267","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"05f711b1-05e6-5832-a014-0d48622761aa","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"2ff5c538-1fb7-5d1b-bd20-0b559053d445","slug":"definition","fullItemName":"Definition"},{"id":"222a21f0-7691-5217-92ac-d0b454809378","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"40912c6f-7953-5028-8087-bfe412fe8144","slug":"prevalence","fullItemName":"Prevalence"},{"id":"0c6caaf8-c9e3-5154-ad85-0639ce885933","slug":"complications","fullItemName":"Complications"},{"id":"7dad7582-0879-5b1d-a434-a7385c6bf62a","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"f0e2a168-bba6-5e5e-9290-792a786adf37","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"18cd5747-18a3-56ba-bc8b-4426d03187a4","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"d17676a0-b0c6-5edc-8a36-71ff56514267","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"5928ae5b-d1b2-5880-b5d0-520d3eefbbb3","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"42122189-74ea-5630-87b7-23f6266addc0","fullItemName":"Management","slug":"management","subChapters":[{"id":"047c46a8-6c2e-538d-b303-898bc35b204c","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"ad839214-35b0-58d1-b8ec-1d66a6be3eb0","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"fa86dcab-a820-5a5f-a76d-e237364c1e7b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"caac4d3d-be17-58bd-b762-bb897b659611","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"7cfd6eb7-5b49-52a2-aa31-f8bf0144547c","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"7e0cae2d-7716-577b-8a6f-249f600698b5","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e8a07059-cd02-573a-819c-26383cacb522","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"d99f4de4-aa27-5079-811c-923190c5046a","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a29113d9-3ec2-598e-9d77-05509c1df517","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e0b8f18b-6f9c-5652-83d0-dafbd8f023f1","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"af7ba7e4-dbd1-5b09-8dd0-23cb1fd03b1f","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 342a03c2-55d4-42e4-a370-8ab90a312abb --><h3>Previous changes</h3><!-- end field 342a03c2-55d4-42e4-a370-8ab90a312abb -->","summary":null,"htmlStringContent":"<!-- begin item 41347ca6-6b93-46cb-9888-bf86ba0fe799 --><!-- begin field c695de56-a09c-4598-931c-3288ce3fe1a4 --><p><strong>August 2013 </strong>— reviewed. A literature search was conducted in July 2013 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. Changes have been made to the Diagnosis and Management sections to provide a more stepped approach to the assessment and management of a person with suspected polymyalgia rheumatica (PMR). These changes reflect recommendations made in the <em>British Society for Rheumatology (BSR) and British Health Professionals in Rheumatology (BHPR) guidelines for the management of polymyalgia rheumatica</em>.</p><p><strong>August 2012 </strong>— minor update. Minor typographical errors corrected.</p><p><strong>February 2010 </strong>— topic structure revised to ensure consistency across CKS topics. No changes to clinical recommendations have been made.</p><p><strong>December 2008 to May 2009 </strong>— converted from CKS guidance to CKS topic structure. The evidence base has been reviewed in detail, and are more clearly justified and transparently linked to the supporting evidence. Together with the CKS topic on <em>Giant cell arteritis</em>, this CKS topic replaces the former topic on <em>PMR and GCA. </em>There have been no major changes to the recommendations.</p><p><strong>September 2008 </strong>— minor correction to the Changes section. Issued September 2008.</p><p><strong>July 2006 </strong>— minor update to include the Commission on Human Medicine (CHM) warning for bisphosphonates and associated osteonecrosis of the jaw. Issued in July 2006.</p><p><strong>June 2005 </strong>— reviewed. Validated in September 2005 and issued in November 2005.</p><p><strong>January 2004 </strong>— updated to incorporate the safety update from the Committee on Safety of Medicines (CSM) advising that hormone replacement therapy (HRT) should no longer be used first-line for the prevention of osteoporosis. Issued in February 2004.</p><p><strong>June 2003 </strong>— updated to incorporate new guidance from the Royal College of Physicians: <em>Glucocorticoid-induced osteoporosis</em>. Validated in September 2003 and issued in October 2003.</p><p><strong>January 2002 </strong>— reviewed. Validated in March 2002 and issued in April 2002.</p><p><strong>June 1999 </strong>— written. Validated in October 1999 and issued in January 2000.</p><!-- end field c695de56-a09c-4598-931c-3288ce3fe1a4 --><!-- end item 41347ca6-6b93-46cb-9888-bf86ba0fe799 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}